2019

Amager Hospital, Denmark has entered an agreement with ViroGates for the use of suPARnostic® TurbiLatex in clinical routine practice for the triage and severity assessment of all acute clinical patients in the Emergency Room.

Meet us at DASEM 2019 - Årsmøde Dansk Selskab for Akutmedicin / Danish Society for Emergency Medicine on April 26-27 in Middelfart, Denmark.

ViroGates announces that the development and regulatory approval of the suPARnostic® TurbiLatex product for Roche Diagnostics cobas c500 and c700 series has been completed.

Meet us at DINK, Deutscher Interdisziplinärer Notfallmedizin Kongress on March 21-22 in Koblenz, Germany and hear about suPARnostic®

Meet us at Emergency Conference SWEET on March 13-15 in Stockholm, Sweden and hear about suPARnostic®

ViroGates announces that the development and regulatory approval of the suPARnostic® TurbiLatex product for Roche Diagnostics cobas c502 has been completed.

New abstract published in Immunity & Ageing;
"Healthy lifestyles reduce suPAR and mortality in a Danish general population study" by Haupt T.H. et al.

New abstract published in World Journal of Surgery;
"Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments" by Alstrup M et al.

ViroGates is expanding and has welcomed 5 new employees since November 1, 2018.

The ViroGates team now includes 4 new members responsible for Sales and Business Development in Scandinavia, Germany, France and Spain, as well as an International Application Scientist.